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Abstract
The pathogenicity of Clostridium difficile is primarily linked to secretion of the intracellular acting toxins A (TcdA) and B
(TcdB) which monoglucosylate and thereby inactivate Rho GTPases of host cells. Although the molecular mode of action of
TcdA and TcdB is well understood, far less is known about toxin binding and uptake. It is acknowledged that the C-
terminally combined repetitive oligopeptides (CROPs) of the toxins function as receptor binding domain. The current study
evaluates the role of the CROP domain with respect to functionality of TcdA and TcdB. Therefore, we generated truncated
TcdA devoid of the CROPs (TcdA
1–1874) and found that this mutant was still cytopathic. However, TcdA
1–1874 possesses
about 5 to 10-fold less potency towards 3T3 and HT29 cells compared to the full length toxin. Interestingly, CHO-C6 cells
even showed almost identical susceptibility towards truncated and full length TcdA concerning Rac1 glucosylation or cell
rounding, respectively. FACS and Western blot analyses elucidated these differences and revealed a correlation between
CROP-binding to the cell surface and toxin potency. These findings refute the accepted opinion of solely CROP- mediated
toxin internalization. Competition experiments demonstrated that presence neither of TcdA CROPs nor of full length TcdA
reduced binding of truncated TcdA
1–1874 to HT29 cells. We assume that toxin uptake might additionally occur through
alternative receptor structures and/or other associated endocytotic pathways. The second assumption was substantiated by
TER measurements showing that basolaterally applied TcdA
1–1874 exhibits considerably higher cytotoxic potency than
apically applied mutant or even full length TcdA, the latter being almost independent of the side of application. Thus,
different routes for cellular uptake might enable the toxins to enter a broader repertoire of cell types leading to the
observed multifarious pathogenesis of C. difficile.
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Introduction
Clostridium difficile associated disease is primarily linked to the
production of the two homologous pathogenicity factors toxin A
(TcdA) and toxin B (TcdB). Both toxins are members of the family
of large clostridial glucosyltransferases that monoglucosylate small
GTP-binding proteins of the Rho family [1]. Glucosylation of Rho
GTPases renders these proteins in their inactive state leading to
breakdown of the actin cytoskeleton with subsequent cell
rounding. In combination with ELISA this cell rounding assay,
also referred to as cytotoxicity assay, is still gold standard when
performed on Vero cells for diagnosis of pathogenic C. difficile
infection.
The toxins are single chain proteins of an A/B type structure
where the catalytic active glucosyltransferase domain is located at
theN-terminusandthe proposedreceptorbindingdomainattheC-
terminus [2]. The C-terminus of TcdA and TcdB consists of 37 or
19 repeats, respectively, building combined repetitive oligopeptide
structures (CROPs) [3–6] from which it is known that they bind to
carbohydrate structures. Detailed studies were performed in the
early1990sand Gala1-3Galb1-4bGlcNAcwas describedasbinding
structure for TcdA. Since this oligosaccharide is not present in
humans, at least a type 2-core with a b1–4 linkage (Galb1–
4bGlcNAc) is essential, which is found on the carbohydrate antigens
I, X, and Y [7]. Additionally, the C-terminal repeats bind Ca
2+
thereby enhancing potency of TcdA [8]. Despite the respective
carbohydrate structure few is known about the nature of the
receptor. Sucrase- isomaltase as well as the glycoprotein gp96 have
been suggested as functional binding proteins or receptor for TcdA
[9,10]. The entry of TcdA and TcdB into the target cell is mediated
by binding to their receptors which triggers endocytosis. Although
the functional receptors for TcdA and TcdB have not been
definitely identified, both toxins seem to have different receptors.
Thecrucialstep forpathogenicityofthetoxinsisthe translocationof
the catalytic domains into the cytosol of target cells. Acidification of
the endosomal vesicular lumen induces conformational changes of
the toxins which allows the insertion into the vesicle membrane and
translocation of the N-terminally located catalytic glucosyltransfer-
ase (GT) domain into the cytosol. The GT-domain is autoproteo-
lytically released from the trunk by a toxin-inherent cysteine
protease domain [11,12].
In 2007, Amimoto and co-workers reported on a novel toxin
homologous to large clostridial glucosylating toxins that is
produced by C. perfringens type C strains [13]. Interestingly, this
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supposed to function as receptor-binding structures, but still
displays cytotoxic activity. Based on this finding we dispute the
necessity of the CROP domain concerning functional properties of
TcdA and TcdB. The current study evaluates the functional role
of the TcdA CROP-domain by utilizing truncated TcdA where
the C-terminal amino acids 1875–2710 were deleted (TcdA
1–1874).
We proved that the C-terminal repeats are not essential for TcdA
function albeit they determine the potency of the toxin by
interacting with surface structures of host cells.
Materials and Methods
Chemicals and reagents
The antibodies used were: polyclonal rabbit antibodies a-
TcdA1–543, a-TcdA1–1065, and a-TcdA1–2710 (Institute of Toxicol-
ogy, Hannover Medical School); a-TcdA1875–2710 (this study);
monoclonal anti-Rac1 antibody (clone 102; BD PharMingen)
recognizing total Rac1; monoclonal anti-Rac1 antibody (clone
23A8; Upstate) recognizing non-glucosylated Rac1; antibody
against b-Actin (clone AC15) was from Sigma; a-EEA1 was
purchased from BD Transduction Laboratories; horseradish-
conjugated goat anti-mouse IgG and goat anti-rabbit IgG were
from Rockland Immunochemicalsand BafilomycinA1 from Sigma.
The Bacillus megaterium expression system was from MoBiTec.
Fluorescent Protein Labeling Kits Lightning-Link
TMPE/Cy5 and
Lightning-Link
TMAtto488 were purchased from Innova Bioscienc-
es. All chemicals were of the highest purity available.
Expression of recombinant toxins
The C. difficile toxins (strain VPI 10463, GenBank accession
no. X51797) were recombinantly expressed in the B. megaterium
expression system as His-tagged fusion proteins (MoBiTec,
Germany). Expression and purification was performed after
standard protocol as described previously (Burger et al., 2003).
Truncated TcdA (amino acids 1–1874) was generated by using a
specific endonuclease recognition site (bp 5620) in TcdA, which is
located within the first repetitive sequence, and cloning of the
resulting toxin fragment into the modified B. megaterium expression
vector pWH1520 [14]. This SpeI recognition site was also used to
mobilize and thereby eliminate bases 1–5622 from the TcdA-
encoding plasmid. Re-ligation of the remaining construct resulted
in generation of pWH-TcdA5623–8130 encoding the amino acids
1875–2710 that correspond to the TcdA CROP domain. The
purified expression product was used for immunization.
The TcdA mutant containing the complete N-terminal domain
and hydrophobic region (TcdA
1–1101) wasgenerated by extension of
construct pWH-TcdA1–3195 encoding amino acids 1–1065 as
described previously (Teichert et. al, 2006). Therefore, a synthesized
oligonucleotide encompassing the tcdA base pairs encoding amino
acids 1066–1101 (sense: 59- TAAGGTGGGTGTTTTAGCAA-
TAAATATGTCATTATCTATAGCTGCAACTGTAG CTTC-
AATTGTTGGAATAGGTGCTGAAGTTACTATTTTCTTA-
TTACCTATAGCTGGTATAGGACATCATCATCATCATC-
ATTAGA-39; antisense: 59- GATCTCTAATGATGAT GAT-
GATGATGTCCTATACCAGCTATAGGTAATAAGAAAAT-
AGTAACTTCAGCACCTATTCCAACAATTGAAGCTACA-
GTTGCAGCTATAGATAATGACATATTTATTGCTAAAA-
CACCCACC-39) were purchased from Biomers (Germany) and
ligated into construct pWH-TcdA1–3195 by Bpu10 and BglII
restriction sites.
To generate EGFP-labelled CROP domain the egfp gene was
amplified from vector pEGFP-C1 (BD Biosciences Clontech) and
inserted at the SpeI site of construct pWH-TcdA5623–8130.
The tcdB gene was amplified from C. difficile (VPI 10463)
chromosomal DNA using forward primer 5’-AGTCTGTA-
CAATGAGTTTAGTTAATAG-39 and reverse primer 59-AGT-
CAG ATCTCTTCACTAATCACTAATTG-39. The PCR prod-
uct was digested by BsrGI and BamHI enzymes and ligated into
pHis1522 vector (MoBiTec, Goettingen, Germany) for production
of full length TcdB. Generation of the construct encoding the
truncated TcdB
1–1852 was achieved by two cloning steps.
Mobilization of the tcdB bases 1–5260 was accomplished by BsrGI
and SpeI restriction digest from the full length construct
pHis1522-TcdB followed by ligation of the fragment into vector
pHis1522. To replenish construct pHis1522-TcdB1–5260 up to base
pair 5556, bases 5261–5556 were amplified (forward primer: 59-
AGCTACTAGTGAAGAAAATAAGGTGTCACAAG-39; reverse
primer: 59-AGCTGGA TCCCCAAATTATTTACTGGTGGT-
TTA-39) and ligated into pHis1522-TcdB1-5260 through SpeI and
BamHI restriction sites. The resulting construct pHis1522-TcdB1–5556
encodes the C-terminal truncated TcdB
1–1852. All constructs were
sequenced.
Generation of specific antibody
Immunization of a female New Zealand rabbit was performed
after standard protocol using the affinity purified immunogen
TcdA
1875–2710 (Permission No. 33-42502-03A351, see Ethics
statement). First immunisation was performed with 100 mgo f
protein followed by a single boost after four weeks. Blood was
collected three weeks after boost immunisation. Specificity of anti-
serum was checked by Western blot using the antigen as control.
Cell culture and cytotoxicity assay
3T3 mouse fibroblasts and the human colon carcinoma cell
CaCo-2 were cultivated under standard conditions in Dulbeccos’
modified Eagle’s medium (DMEM) supplemented with 10% foetal
bovine serum (FBS), 100 mM penicillin, 100 mg/ml streptomycin,
and for CaCo-2 cells only 1% non-essential amino acids (NEA)
[15,16]. The human colonic crypt cell line HT29 was grown in
DMEM/Ham’s F-12 supplemented with 10% fetal bovine serum,
100 mM penicillin and 100 mg/ml streptomycin. The hamster ovar
cells CHO-C6 were cultivated in DMEM/Ham’s F-12 supple-
mented with 5% fetal bovine serum, 1 mM sodium pyruvate,
100 mM penicillin and 100 mg/ml streptomycin [17]. For
cytotoxicity assay, cells were seeded in 24-well chambers and
grown for 24 hours to sub-confluence. Toxins were diluted in the
respective medium and indicated concentrations were added in
appropriate volumes to the indicated cells. For inhibitor
experiments, 3T3 fibroblasts were pre-treated with Bafilomycin
A1 (100 nM) for 5 min followed by application of indicated toxins
or toxin fragments, respectively. Toxin-induced cell rounding was
monitored by light microscopy and cytopathic effect (CPE) was
quantified as round cells per total cells. The cell lysates of toxin-
treated cells were subjected to SDS-PAGE and Western blot
analysis to determine status of Rac1-glucosyalation as direct
marker for intracellular action of toxins. Specific antibodies were
used recognizing either only non-glucosylated Rac1 (clone 23A8)
or total Rac1 (clone 102). For internalization assays, Bafilomycin
A1 was applied to 3T3 fibroblasts at indicated time points in
relation to toxin treatment and the cytopathic effect was
determined as described above.
Fluorescent Toxin Labeling
TcdA and TcdA
1–1874 were labeled with Lightning-Link
TM PE-
Cy5 and Lightning-Link
TM Atto188, respectively, according to the
manufacture’s instructions. In brief, the lyophilized fluorophor was
dissolved in toxin solution supplemented with LL-Modifier
CROP-Mediated Endocytosis of TcdA
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stopped by addition of LL-Quencher FD reagent. TcdA was
conjugated to the tandem fluorophor PE/Cy5 and TcdA
1–1874 to
the fluorescent dye Atto488 giving a toxin concentration of 2–
5 mM.
Binding assay and Fluorescence-activated cell sorting
(FACS)
For comparative binding studies to intact cells, cells grown in
24-well chambers were incubated for 30 min on ice with 6 nM of
TcdA or TcdA
1–1874. Cells were washed twice in phosphate-
buffered saline (PBS) to eliminate non-bound toxins and lyzed in
1x La ¨mmli, supplemented with 100 mM 4-(2-Aminoethyl)-ben-
zensulfonylfluorid (AEBSF). Lysates were subjected to SDS-PAGE
and Western blot analysis to detect the level of bound toxins.
Binding of the CROPs and the toxins TcdA and TcdA
1–1874 to
the cell surface was additionally analyzed by flow cytometry.
Therefore, adherent cells were suspended by Accutase treatment
and 500,000 cells were incubated at 4uC for 30 min with indicated
concentrations of EGFP, EGFP-fused TcdA
1875–2710 or fluorescent
labeled TcdA (TcdA-PE/Cy5) and TcdA
1–1874 (TcdA
1–1874-
Atto488), respectively. Under standard conditions cells were
washed twice with ice-cold PBS by centrifugation at 200 g for
5 min at 4uC to eliminate non-bound toxins. Except for
fluorescent labeled toxins (TcdA-PE/Cy5 and TcdA
1–1874-
Atto488) cells were subsequently fixed in 4% of formaldehyde
solution, repeatedly washed and finally subjected to flow cytometry
(FACScan flow cytometer; Becton Dickinson). Ten thousand
events were monitored per condition.
For competition assays 500,000 HT29 cells were pre-incubated
for 30 min at 4uC in 25-fold excess with indicated concentrations
of non-labeled TcdA, TcdA
1–1874 or TcdA
1875–2710, respectively,
to saturate all binding sites. Except when otherwise described, cells
were washed to eliminate non-bound protein and incubated with
either PE/Cy5-labeled TcdA, Atto488-conjugated TcdA
1–1874 or
both or EGFP-fused TcdA
1875–2710, respectively. Toxins were
applied to the cells at indicated concentrations and fluorescence
activity was monitored with and without pre-treatment as
described above.
Immunofluorescence microscopy
HT29 cells grown on coverslips were incubated on ice for
30 min with 80 nM of EGFP or EGFP-labelled TcdA
1875–2710,
respectively, followed by several washing-steps with ice cold PBS.
Cellular uptake was allowed by addition of 37uC-warmed PBS
supplemented with 2 mM CaCl2 2 mM MgSO4 (pH 7.4) and
incubation at 37uC. At indicated time points cells were washed
twice with PBS, fixed with 4% paraformaldehyde/sucrose solution
and permeabilized for 5 min with 0.2% Triton X-100 in PBS.
Coverslips were blocked for 1 h with 10% BSA in PBS and stained
with EEA-1 antibody (1:1000 in 1% BSA in PBS) for 1 h followed
by staining with Alexa-Fluor 594 conjugated goat anti-mouse
secondary antibody (1:5000 in 1% BSA in PBS) for 45 min.
Simultaneously, nuclei were counterstained with DAPI and
coverslips were mounted onto glass slides and subjected to
confocal laser scanning microscopy (Leica Inverted DM IRE 2).
Neutralizing experiment
CHO-C6 cells were grown in 24-well chambers for 24 h under
standard conditions. Prior to the experiment, 100 mlo f2 0n M
TcdA or TcdA
1–1874, respectively, were diluted 1:1 either with
PBS or with antiserum a-TcdA1875–2710 and incubated for 20 min
at RT in a rotating manner. Following pre-treatment, toxin/PBS-
and toxin/antiserum-mixtures, respectively, were applied to the
cultivated CHO-C6 cells at final concentration of 1 nM. Cell
rounding of the cells was monitored by light microscopy as marker
for toxin uptake and activity. After incubation for 5 h at 37uC,
cytopathic effect was quantified as round cells per total cells [%].
Values are given as means 6 SD, n=5.
Western blotting
Protein samples were separated by SDS-PAGE and transferred
onto nitrocellulose membrane. After blocking with 5% (w/v)
nonfat dry milk in TBST (50 mM Tris HCl pH 7.2, 150 mM
NaCl, 0.05% (v/v) Tween-20) the membrane was incubated
overnight with the primary antibody at 4uC. Following washing
with TBST it was incubated for 1 h at room temperature with
horseradish peroxidase conjugated secondary antibody (Rockland,
USA). Detection was performed by means of chemiluminescence.
TER measurement
CaCo-2 cells were seeded onto 12 well filter inserts (Transwell,
pore size 0.4 mM, (Becton Dickinson, Germany) to measure the
transepithelial electrical resistance (TER). Monolayers were
cultivated up to an initial resistance of .150 V*cm
2. The TER
was determined by epithelial Voltohmmeter (EVOM, World
Precision Instruments, Germany) equipped with Endom 24
chamber. To investigate toxin-induced deregulation of the
intestinal barrier function, cells were apically or basolaterally
treated with 1 nM of TcdA and TcdA
1–1874 or 100 pM of TcdB
and TcdB
1–1852, respectively, and TER was measured at indicated
time points. Values are given as means6standard deviations
(N=3).
Ethics Statement
This study was conducted in accordance with German law for
animal protection and with the European Communities Council
Directive 86/609/EEC for the protection of animals used for
experimental purposes. All protocols were approved and exper-
iments were permitted by the local government (permission
No. 33-42502-03A351 by the Lower Saxony State Office for
Consumer Protection and Food Safety, LAVES, Oldenburg,
Germany) and approved by the Local Institutional Animal Care
and Research Advisory committee represented by the institutional
animal welfare officer and head of the Institute for animal Science,
Hannover Medical School, Prof. Dr. Hans-J. Hedrich.
Results
The CROP domain of TcdA is not solely responsible for
toxin uptake
Based on the literature we dispute the necessity of the C-terminal
repeats for toxin functionality. Therefore we generated mutant
TcdA lacking the supposed receptor binding domain (TcdA
1–1874)
and investigated the cytopathic impact towards host cells in cell
rounding and Rac1-glucosylation assay (Fig. 1 B,C). Although
lacking the receptor binding domain, TcdA
1–1874 (1 nM) possesses
cytopathic potency when applied to 3T3 fibroblasts. Instead, mutant
TcdA
1–1101, consisting of the N-terminal domain and the hydro-
phobic region, did not induce cell rounding or Rac1-glucosylation
excluding non-specific uptake of TcdA
1–1874 (Fig. 1B). Even at 300-
fold higher concentration (300 nM) TcdA
1–1101 did not show any
signs of cytotoxicity after 48 h (data not shown). In addition,
Bafilomycin A1, an inhibitor of endosomal acidification, prevented
TcdA
1–1874-induced cytopathic effects reflecting that this CROP-
deletion mutant is also internalized by receptor-mediated endocy-
tosis (Fig. 1D).
CROP-Mediated Endocytosis of TcdA
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neutralizing experiments with polyclonal antiserum raised against
the amino acids 1875–2710 were performed. Dot blot analysis
and ELISA confirmed specificity of a-TcdA1875–2710 (Fig. 2A,B).
As supposed, a-TcdA1875–2710 prevented the cytopathic effect of
full length TcdA over the observed period of 5 h (Fig. 2C)
implying a crucial role for the repetitive sequences with regard to
toxin functionality. Interestingly, the strong cytopathic effect
induced by TcdA
1–1874 was not affected by this antiserum
strengthening the hypothesis that the CROPs do not constitute
the sole receptor binding domain. To further characterize the
CROP-independent impact full length and truncated TcdA were
compared in cell rounding assays to measure their cytopathic
potency and with respect to intracellular glucosylation of Rac1.
Glucosylation of Rac1 was indirectly detected by Western blot
with specific antibody only recognizing non-glucosylated Rac1
[18]. Fig. 3A exemplarily shows concentration-dependent de-
crease of non-glucosylated Rac1 levels in comparison to total
Rac1 of HT29 cells. Dose- dependent rounding of cells
(cytopathic effect, CPE) showed half-maximum effect (EC50)a t
Figure 1. TcdA
1–1874 lacking the C-terminal repeats still possesses cytotoxic potency. A) Multidomain structure of C. difficile TcdA and
TcdA mutants TcdA
1–1874 and TcdA
1–1101. Full length TcdA consists of the N-terminal glucosyltransferase domain (GTD), the cysteinprotease domain
(CPD), the hydrophobic region (HR) acting as transmembrane domain and the C-terminal combined repetitive oligopeptides (CROPs). The CROPs
were deleted in TcdA
1–1874. Mutant TcdA
1–1101 exhibits the whole N-terminal domain including the hydrophobic region. B) Cell rounding assay of 3T3
fibroblasts after 90 min of toxin treatment with 1 nM of TcdA, TcdA
1–1874 or TcdA
1–1101, respectively. C) Western blot analysis of toxin-treated cells
using antibody either recognizing only non-glucosylated (upper panel) or total Rac1 (lower panel). D) Pre-treatment of 3T3 fibroblasts with 100 nM of
Bafilomycin A1, an inhibitor of endosomal acidification, prevents cell rounding of TcdA and TcdA
1–1874 revealing specific cellular uptake of CROP-
truncated TcdA. Cells were treated with equipotent concentrations of TcdA (1 nM) and TcdA
1–1874 (10 nM) for 2 h.
doi:10.1371/journal.pone.0017623.g001
CROP-Mediated Endocytosis of TcdA
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the mutant TcdA
1–1874 (Fig. 3B, middle panel). Rac1-glucosyla-
tion was 5-fold reduced for TcdA
1–1874 compared to full length
TcdA. The discrepancy between CPE and Rac1-glucosylation is
due to the need of almost quantitative Rac1-glucosylation to
achieve complete cell rounding. Similar results were found for
3T3 fibroblasts, although these cells were 5-fold more sensitive
than HT29 cells. Compared to full length TcdA, the cytopathic
potency of TcdA
1–1874 towards 3T3 fibroblasts was about 10-fold
reduced with respect to cell rounding assay (EC50:8 3p Mvs.
989 pM) and about 5-fold reduced with respect to Rac1
glucosylation (EC50:8p Mvs. 41 pM). Interestingly, CHO-C6
cells show almost identical susceptibility towards full length and
truncated TcdA regarding cytopathic effect (EC50:2 2 3p Mvs.
203 pM) and Rac1-glucosylation status (EC50:1 3 0 p Mvs.
121 pM). All data are summarized in table 1.
We additionally performed FACS-analysis with EGFP-fused
CROPs to investigate binding of the repetitive sequences to
different host cells. In order to determine the amount of protein
necessary to saturate binding sites, HT29 cells were incubated with
increasing amounts of EGFP-TcdA
1875–2710. FACS analysis
revealed that saturation of binding was achieved by application
of 1–2 mg protein to 500,000 cells (Fig. 4A). To examine binding
specificity of the EGFP-fused CROP domain, competition assay
was performed. Fig. 4B nicely shows that pre-incubation of HT29
cells with non-labeled CROPs reduced the amount of bound
EGFP- TcdA
1875–2710 dramatically indicating that EGFP-labeling
does not alter binding properties of the CROPs. We therefore used
Figure 2. Neutralization assay emphasizes the role of TcdA CROPs in toxin functionality. A) Dot blot showing specificity of generated
polyclonal antiserum a-TcdA1875–2710. The antiserum raised against the CROPs of TcdA only recognizes full length TcdA as well as the isolated CROP
domain TcdA
1875–2710. No cross-reactivity was detected towards CROP-truncated TcdA
1–1874 or native TcdB, respectively. B. megaterium lysate was
used as negative control. B) Recognition of full length toxin or toxin fragments by a-TcdA1875–2710 was checked by ELISA. A 96-well plate was coated
with full length TcdA, TcdA
1–1874 and TcdA
1875–2710, respectively. The bar diagram shows absorption at 405 nm after concentration-dependent
binding of a-TcdA1875–2710 to full length TcdA and the C-terminal repeats. Binding to TcdA
1–1874 was only observed to a small extent and after
applying high amounts of antiserum (dilution factor 1:100). Values are given as means 6 standard deviation, n=5. C) Neutralization of TcdA and
TcdA
1–1874 with a-TcdA1875–2710 antiserum was investigated in CHO-C6 cell rounding assay (left panel). Cytopathic effect (CPE) was quantified as
round cells per total cells in %. Values are given as means 6 SD, n=5 (right panel).
doi:10.1371/journal.pone.0017623.g002
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the C-terminal repeats of TcdA strongly bound to 3T3 and HT29
cells, as shown by curve shift in Fig. 4C (left and middle panels,
black curve). Interestingly, no binding of the CROPs to CHO-C6
cells was observed. This is in accordance with cell rounding and
Rac1-glucosylation assays where CHO-C6 cells were as sensitive
to full length as to truncated TcdA
1–1874 (compare Fig. 3, lowest
panel). Similar to the effects observed for TcdA, CROP-deleted
Figure 3. Cytotoxic potency of TcdA and TcdA
1–1874 towards host cells. A) HT29 cells were treated with full length TcdA or TcdA
1–1874 in a
concentration-dependent manner until onset of cell rounding. Western blot analysis was performed to monitor level of glucosylated Rac1 using
antibodies recognizing either non-glucosylated Rac1 (upper panel) or total Rac1 (lower panel), respectively. B) Dose-dependent analysis of cytopathic
effect (CPE) and Rac1-glucosylation induced by TcdA (N) and TcdA
1–1874 (,) on 3T3, HT29 and CHO-C6 cells. Cytopathic effect was quantified as
round cells per total cells in %. Results of Rac1-glucosylation are based on immunoblot analyses exemplarily shown in A). Values are given as means
6 SD, n=3.
doi:10.1371/journal.pone.0017623.g003
CROP-Mediated Endocytosis of TcdA
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1–1852) is still cytopathic towards all used cell lines
(data not shown). However, in any case TcdB was more potent
than TcdB
1–1852. These data nicely indicate that repeats in the C-
terminus of TcdA modulate the potency of TcdA and TcdB
towards a variety of cells. There are, however, exceptions where
the CROPs of TcdA do not develop this effect, as shown by
treatment of CHO-C6 cells. Towards these cells, full length TcdA
and truncated TcdA possess comparable potency. Thus, CROP-
binding to the cell surface basically correlates with toxin potency.
These findings refute the accepted opinion of a solely CROP-
mediated toxin uptake. Toxin internalization into host cells might
additionally occur through an alternative receptor structure and/
or corresponding endocytotic pathway.
The CROP domain triggers high rated endocytosis
Since the approach of binding studies of the isolated, epitope-
labelled domains to suspended cells is very artificial we further
characterized and compared binding of the full length and
truncated TcdA to cell surfaces of intact cells. In order to identify a
specific antibody detecting full length and truncated TcdA with
same sensitivity, different polyclonal antisera were tested by
Western blot analyses. Fig. 5A displays strong and comparable
recognition of TcdA and TcdA
1–1874 by antiserum a-TcdA1–1065,
for which reason this antibody was used for further studies.
It is noteworthy that in immunoblot analyses full length and C-
terminal deleted TcdA bind in a comparable manner to 3T3 or
HT29 cells (Fig. 5B) though monitoring an almost 10-fold reduced
CPE of TcdA
1–1874 compared to full length TcdA (compare Fig. 3).
In order to support this observation, binding was additionally
analyzed by flow cytometry with fluorescent labeled toxins
(Fig. 5C). Labeled toxins still possess cytopathic activity as checked
Table 1. EC50 [pM] of TcdA and TcdA
1–1874 regarding
cytopathic effect and Rac1-glucosylation.
Cytopathic effect Rac1 glucosylation
EC50 [pM] TcdA TcdA
1–1874 TcdA TcdA
1–1874
3T3 83 989 10 68
HT29 549 5309 41 198
CHO 223 203 130 121
doi:10.1371/journal.pone.0017623.t001
Figure 4. Binding of TcdA CROPs to host cells. A) Suspended HT29 cells were incubated at 4uC with increasing amounts of EGFP-labelled
TcdA
1875–2710 to determine optimal protein-to-cell ratio for binding studies. FACS analysis revealed saturation of binding at 1 mg protein per 500,000
cells. B) HT29 cells were pre-treated with 5 mg/ml non-labelled TcdA
1875–2710 followed by incubation with 1 mg/ml EGFP-labelled TcdA
1875–2710 to
examine binding specificity of the fusion protein by FACS analysis. Right shift of the light grey curve to higher fluorescence reflects binding of EGFP-
TcdA
1875–2710 to HT29 cells. Competition with non-labelled CROP domain reduced binding (black curve) revealing same specificity of the fusion
protein. EGFP alone was used as negative control (dark grey). C) FACS analysis with EGFP (grey curve) or EGFP-labelled TcdA CROP domain (black
curve) was performed to study CROP binding to different host cells. As shown by right shift of the black curve TcdA CROPs strongly bind to 3T3 and
HT29 cells whereas faint binding was monitored to CHO-C6 cells.
doi:10.1371/journal.pone.0017623.g004
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This approach also confirmed specific binding of full length as well
as of CROP-truncated TcdA to HT29 cells. The difference in
fluorescence intensities is a result of different fluorescent labeling of
TcdA and TcdA
1–1874 (TcdA-PE/Cy5 and TcdA
1–1874-Atto488)
as well as of different labeling ratio due to size of toxins. Thus,
these data should be interpreted qualitatively. Both, TcdA as well
as TcdA
1–1874, bind to HT29. Interestingly, as confirmed by both
approaches, CHO cells showed enhanced binding of truncated
TcdA and no binding of the full length protein (Fig. 5B, bottom
panel and Fig. 5C, lower panel) though being identical susceptible
towards both toxins (compare Fig. 3). These findings imply that
TcdA
1–1874 binds to abundant receptor structures with low uptake
rate whereas CROP- specific binding structures, indeed, are rare
but ensure potent uptake. To substantiate this hypothesis, uptake
efficiencies of TcdA and TcdA
1–1874 into host cells were
Figure 5. Binding of TcdA and TcdA
1–1874 to host cells. A) The polyclonal antisera a-TcdA1–2710, a-TcdA1–1065 and a-TcdA1–543 were tested by
Western blot analyses to identify a specific antibody detecting full length and truncated TcdA with same sensitivity. Antiserum a-TcdA1–1065 was
selected for further studies showing strong and comparable recognition of TcdA and TcdA
1–1874. B) Binding of TcdA and TcdA
1–1874 to intact 3T3,
HT29 and CHO-C6 cells was performed for 30 min at 4uC and analyzed by Western blot with a-TcdA1–1065. C) Binding of fluorescent labeled TcdA-PE/
Cy5 and TcdA
1–1874-Atto488 to HT29 and CHO-C6 cells was investigated by FACS analysis. Right shift of the black curve illustrates toxin binding which
was detected through fluorescence emission at 667 nm for TcdA and at 523 nm for TcdA
1–1874, respectively. Due to different ratio of fluorophor and
toxin, fluorescence intensity of TcdA-PE/Cy5 cannot directly be compared with TcdA
1–1874-Atto488.
doi:10.1371/journal.pone.0017623.g005
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tion following endosomal acidification was monitored as indirect
marker for endocytosis rate. Following binding of TcdA and
TcdA
1–1874 at 4uC to HT29 cells, endocytotic toxin-uptake was
induced by temperature-shift to 37uC. At the indicated time-points
cells were lyzed and lysates were subjected to Western blot analysis
to detect non-degraded toxins. In fact, degradation of TcdA
1–1874
occurred with a marked delay compared to TcdA revealing a faster
endocytoticprocessofthefulllengthtoxin(Fig.6A).Thisnotionwas
corroborated by another approach. Bafilomycin A1 was applied to
HT29 cells at different time points after treatment with TcdA or
TcdA
1–1874 to inhibit endosomal acidification. As nicely shown in
Fig. 6B, endocytosis of full length TcdA was prevented by
Bafilomycin A1 only when applied within 5 min after toxin
treatment. Inhibition of endocytosis 10 min after toxin treatment
did not prevent TcdA uptake,as monitored by 80%of cell rounding
(Fig. 6B,N). Instead, endocytosis of truncated TcdA
1–1874 could still
be inhibited (at least for 3 h of incubation) by Bafilomycin A1 when
applied 15 min after toxin treatment (Fig. 6B, %). These data are in
good agreement with immunoblot analyses shown in Fig. 6A.
Interestingly, confocal microscopy revealed comparable time-
dependent uptake of EGFP-labeled CROP domain (EGFP-
TcdA
1875–2710) compared to full length TcdA. Five minutes
following temperature shift, EGFP-TcdA
1875–2710 strongly bond
to the surface of HT29 cells (Fig. 6B, green). After 10 min of
incubation, CROPs were almost completely endocytosed as
monitored by disappearance of green fluorescence at the cell
surface. In addition, EEA1 were stained to visualize early
endosomes. Simultaneous emergence of yellow spots inside the
cells reflects EGFP-labeled CROPs co-localized with EEA1 in
early endosomes after 10 min. Continuous lysosomal degradation
of internalized TcdA fragments was monitored by a reduction of
co-localized signals after 15 min accompanied by appearance of
red-stained recycled early endosomes. This finding is in accor-
dance with uptake rates determined by Western blot analysis for
full length TcdA (Fig. 6A, left panel). We concluded that uptake of
TcdA might be predominantly mediated by the C-terminal repeats
ensuring potent toxin internalization. Cellular uptake of CROP-
truncated TcdA
1–1874 occurred with a marked delay supporting
the notion of at least one alternative route that can be used by the
toxin.
Cytopathic potencies of full length and CROP-deleted
toxins A and B towards polarized cells depend on the site
of application
To further investigate an alternative internalization mechanism
for CROP- truncated C. difficile toxins, toxin uptake into polarized
CaCo-2 cells was analyzed. CaCo-2 cells serve as model for
different receptor structures and/or protein composition of the
apical and basolateral membrane. Toxin-induced disturbance of
the intestinal barrier function, monitored by reduction of
transepithelial electrical resistance (TER), was measured as marker
for toxin internalization. In coherence with previous data [19],
TcdA possesses almost identical cytotoxicity when applied apically
or basolaterally (Fig. 7A %,&) whereas cytotoxic potency of TcdB
strongly depends on the site of application (Fig. 7B %,&).
Interestingly, basolaterally applied TcdA
1–1874 exhibits consider-
ably higher cytotoxic potency than apically applied or even full
length TcdA. This observation was confirmed by intracellular
Rac1-glucosylation (data not shown). In contrast to TcdA, TcdB
was more potent than its truncated form TcdB
1–1852, independent
on the site of application. Thus, the CaCo-2 model is a cell line
where different endocytotic routes are present and can be studied
separately. These findings strongly speak in favor for different
uptake routes than for cell specific differences in endocytosis of
toxins.
TcdA and TcdA
1–1874 did not compete for cellular
receptors
To further elucidate the cellular binding structures of full length
and truncated TcdA, competition experiments were performed
and evaluated by flow cytometry. Therefore, fluorescent labeled
TcdA and TcdA
1–1874 were applied to HT29 cells either
separately, in combination or simultaneously after saturation of
the cell surface structures with TcdA
1875–2710 (Fig. 8A). Fluores-
cence emission at 667 nm (Fig. 8A, upper panel) and 523 nm
(Fig. 8A, lower panel) revealed binding of TcdA and TcdA
1–1874,
respectively (red curves). Interestingly, presence of TcdA appar-
ently did not affect binding of TcdA
1–1874 to HT29 cells (lower
panel, green curve). This finding implies that truncated TcdA
utilizes other receptor structures for cellular uptake than the full
length toxin. However, a slightly reduced binding capacity of
TcdA was observed in the presence of its truncated form (upper
panel, compare green and red curves). As expected, the isolated
TcdA CROPs (TcdA
1875–2710) clearly compete with the full length
toxin for binding structures at the cell surface of HT29 cells (upper
panel, compare blue and red curves). Surprisingly, pre-incubation
with TcdA
1875–2710 dramatically increased fluorescence intensity
emitted from Atto488- labeled TcdA
1–1874 (lower panel, blue
curve) implying enhanced binding of TcdA
1–1874 to HT29 cells. It
is conceivable that this phenomenon is due to binding of truncated
toxin to the isolated CROP domain immobilized at the cell
surface. This hypothesis is supported by an experiment illustrated
in Fig. 8B. HT29 cells were saturated with either TcdA
1875–2710 or
TcdA
1–1874 followed by immediate addition of EGFP-fused
TcdA
1875–2710. Following incubation, cells were washed and
analyzed by flow cytometry. As expected, the isolated TcdA CROPs
compete with the EGFP-labeled CROP domain (Fig. 8B, compare
blue and black curves). Surprisingly, this seemed to be true for
truncated TcdA
1–1874 as well (compare green and black curves). In
accordance with the conclusion drawn from Fig. 8A, we hypothe-
sized that the excess of TcdA
1–1874 sequestered the CROPs in
solution resulting in a signal reduction of cell-bound TcdA
1875–2710
afterwashing.Thisassumption wasconfirmedbya second approach
in which the excessive putative competitor TcdA
1–1874 was washed
off the cells before subsequently the TcdA CROPs were allowed to
bind the respective receptor structures. In fact, the apparent
competition between TcdA
1–1874 and TcdA
1875–2710 disappeared
under this condition, emphasizing that full length and CROP-
truncated TcdA bind different surface structures.
Discussion
The current study investigates the role of the C-terminal repeats
of C. difficile TcdA regarding toxin functionality. The report by
Amimoto [13] showed that the novel identified TpeL from C.
perfringens, which is homologous to large clostridial glucosylating
toxins, possesses cytotoxic activity. This toxin, however, lacks the
C-terminal repeats that are typical for clostridial glucosyltransfer-
ases and serve as receptor binding domain. Based on this finding
we dispute the necessity of the CROP domain concerning
functional properties of the C. difficile toxins A and B. By
recombinant expression and purification of full length TcdA and
truncated TcdA
1–1874 we were able to compare the cytopathic
impact of both TcdA forms. Indeed, CROP-truncated TcdA
1–1874
induced time- and concentration dependent rounding of host cells.
Since the N-terminal- and transmembrane domain-covering
mutant TcdA
1–1101 was completely inactive in cell rounding and
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1–1874 and TcdA
1875–2710. A) Efficiencies of TcdA and TcdA
1–1874 uptake into HT29 cells were indirectly
determined by monitoring lysosomal toxin degradation following endosomal acidification. After binding at 4uC, endocytosis of toxin was allowed by
temperature shift to 37uC. At the indicated time-points cells were lyzed and lysates were subjected to Western blot analysis to detect non-degraded
toxins. b-Actin served as control protein excluding non-specific protein degradation. B) TcdA or TcdA
1–1874 was applied to 3T3 fibroblasts (time point
0) and Bafilomycin A1 was added at indicated times before or after toxin application. Cell rounding (CPE) was quantified 3 h after toxin treatment as
rounded cells per total cells in %. Values are given as means 6 SD (N=3). C) Endocytosis of the isolated TcdA CROP domain (TcdA
1875–2710) was
proven by immunofluorescence microscopy. Binding of EGFP or EGFP- labeled TcdA
1875–2710 to HT29 cells were performed on ice followed by a
temperature-shift to 37uC allowing endocytotic processes. At indicated time points, cells were washed and fixed and immunofluorescence
microscopy was performed to display nuclei (DAPI, blue), TcdA
1875–2710 (EGFP, green) and early endosomes (EEA1, red). Untreated (ctr) and EGFP-
bound cells (EGFP) were used as controls. The lower panels illustrate magnification of an area indicated by rectangles in the upper panels.
doi:10.1371/journal.pone.0017623.g006
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tion prevented TcdA
1–1874-induced effects, we excluded non-
specific cellular uptake. This was in line with previously reported
lack of cytotoxic potency of TcdA
1–1065 [20].
Recently, Demarest and co-workers described potent toxin
neutralization by a combination of monoclonal antibodies directed
against multiple sites of TcdA localized within the proposed
receptor binding domain [21]. This is in absolute accordance with
our findings and the question arises why antibody solely directed
against the C-terminal repeats is able to neutralize the effect of
TcdA. This phenomenon might be explained by simultaneous
steric inhibition of the vicinal intermediate domain or by hindering
conformational changes of the domains as a prerequisite for
binding to the functional receptor.
In this study we clearly show that TcdA can display its
cytopathic action in the absence of the C- terminal repeats. This
finding is new and puts light on the intermediate and
transmembrane domain as target for further receptor interaction.
It can be assumed that the same is true for TcdB. In coherence
with our data, Barroso and co-workers found that the cytotoxic
properties of E. coli lysates transfected with the corresponding
truncated tcdB gene was about 10-fold reduced compared to lysates
from full length TcdB transfected ones [22]. Despite the nature of
the toxin itself, our data indicate that different cells are differently
sensitive to TcdA because of the interaction with the C-terminal
repeats. As can be deduced from EC50-values of Rac1-glucosyla-
tion (see Tab. 1), which is a direct marker of intracellular toxin
action, the potency of TcdA lacking the CROPs differs less than 3-
fold with respect to different cell types and species. In contrast, full
length TcdA varies 3–10-fold in its potency, pointing out that
sensitivity of cells towards TcdA is primarily defined by the
interaction with the CROPs. This notion is supported by data
from flow cytometry revealing that CROP binding to host cells
correlates with increased potency of TcdA compared to truncated
TcdA
1–1874.
Binding of TcdA
1–1874 was analyzed by Western blots. Although
TcdA
1–1874 was 10-fold less cytopathic compared to TcdA,
binding of both toxins to HT29 cells was comparable. This
discrepancy was even more obvious in CHO cells which exhibit
enhanced binding of truncated TcdA with identical susceptibility
towards both toxins. This raises the question about correlation of
cell surface binding and endocytotic uptake. Comparative analyses
of endocytosis efficiencies revealed that the described phenomenon
is most likely due to a faster internalization process of full length
TcdA compared to truncated TcdA
1–1874. Confocal microscopy
revealed that the TcdA CROPs alone are sufficient in triggering
efficient endocytosis which occurred with rates almost identical to
those observed by full length TcdA (Fig. 6). From these findings we
concluded that uptake of full length TcdA is predominantly
mediated by the C-terminal repeats. Most likely, TcdA
1–1874
abundant receptor structures with low uptake rate whereas
CROP- specific binding structures are less abundant but ensure
potent internalization. The weak binding of full length TcdA to
many cell surfaces compared to the truncated toxin might reveal
that the CROPs mask alternative binding structures of the native
toxin. This hypothesis is supported by a very recent publication of
Pruitt and co-workers who elucidated variability in the structural
organization of the functional toxin domains in pH- dependence
[23]. New perceptions strongly indicate that the glucosyltransfer-
ase domain interacts with the C- terminally located CROPs and
undergoes significant conformational changes following endoso-
mal acidification leading to uncovering of the proposed alternative
binding structures. It is conceivable that exposition and binding of
these structures to the endosomal membrane is a prerequisite for
translocation. Since cholesterol was shown to be essential for
TcdA- and TcdB- mediated pore formation [24], it might be
conceivable that a cholesterol binding region is sufficient for cell
attachment allowing subsequent endocytosis. We previously
reported that toxin fragments that encompass the CROPs plus a
great part of the intermediate domain show stronger competition
with full length TcdA than the mere CROPs [25]. That study
nicely support that the CROPs are not solely responsible for
binding and uptake of at least TcdA. The question, however, arises
whether full length and truncated TcdA utilize different receptor
structures and/or different routes for cellular uptake. We therefore
investigated potential competition between TcdA, TcdA
1–1874 and
TcdA
1875–2710 for cell binding by FACS analyses. Interestingly,
neither full length TcdA nor the isolated CROPs compete with the
truncated toxin for binding sites at HT29 cells indicating that
TcdA
1–1874 and TcdA
1875–2710 bind to different surface structures
Figure 7. Effect of full length and CROP-deleted C. difficile toxins on intestinal barrier function following apical or basolateral
uptake. A) 1 nM of TcdA (%,&) and TcdA
1–1874 (D,m) and B) 100 mM of TcdB (%,&) and TcdB
1–1852 (D,m) were applied to the apical (filled symbols)
or basal (open symbols) compartment of CaCo-2 cells grown on Transwell filter inserts. Transepithelial electrical resistance (TER) was monitored over
time as marker for toxin-uptake and activity. Untreated cells were used as control. Values are given as % of initial value after equilibration as means 6
SD, n=3.
doi:10.1371/journal.pone.0017623.g007
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1875–2710 resulted in
enhanced fluorescence intensity emitted from truncated TcdA
which might be based either on binding of the N-terminal domain
of TcdA
1–1874 to the immobilized CROPs or to a potentially
activated receptor. The first assumption refers to the study of
Pruitt and co-workers who described an interaction of the
glucosyltransferase domain of TcdA to its repetitive sequences at
neutral pH [26]. Since CROP-truncated TcdA lacks its auto-
ligand, the N-terminus might interact with CROPs immobilized at
the cell surface leading to the observed dramatic increase of
fluorescence intensity. The observation of TcdA
1–1874 sequestering
the CROPs in solution additionally supports this hypothesis
(Fig. 8B,C). Another reason for increased fluorescence intensity of
truncated TcdA following pre-incubation with TcdA
1875–2710
could be the nature of the receptor: Binding of the CROPs to
the cell surface might induce conformational changes and activates
the specific receptor. This might be a prerequisite for binding of
TcdA
1–1874 through binding sites located in the intermediate part
of the toxin. Hence, uptake of full length TcdA might occur in a
two-step process explaining the potent endocytosis and increased
toxin potency observed towards many cells compared to the
truncated toxin. Even if the hypothesis has to be examined in more
detail, we conclude that TcdA and TcdA
1–1874 predominantly
bind to different but not independent receptor structures.
We further investigated the hypothesis that internalization of
TcdA and/or TcdB additionally occur via alternative routes. This
hypothesis was evaluated and substantiated by comparative
analyses of the toxin-induced reduction of transepithelial electrical
resistance following apical or basolateral toxin uptake into CaCo-2
cells. Basolaterally applied TcdB possesses considerably higher
potency in destroying epithelial integrity of monolayer than
apically applied TcdB. This observation implies that expression of
the TcdB-specific receptor is more or less restricted to the
basolateral membrane, as also suggested by Stubbe and co-
workers [19]. This discrepancy in sensitivity of apical and
basolateral membrane surfaces was also observed towards
CROP-deleted TcdB (TcdB
1–1852), although TcdB
1–1852 was less
potent than full length TcdB. Interestingly, this was not the case
regarding TcdA. While potency of full length TcdA is almost
independent of the site of application, basolateral membranes
show considerable increased endocytotic capacity towards CROP-
truncated TcdA, resembling those effects observed for TcdB. This
finding emphasizes the assumption of an additional alternative
uptake process, at least for TcdA, which still might be based either
on the recognition of different receptor structures or on the use of
other associated endocytotic pathways. Thus, different routes for
cellular uptake might enable the toxins to enter a broader
repertoire of cell types leading to the observed multifarious
pathogenesis of C. difficile.
The current study proved that the C-terminal repeats (CROPs)
of TcdA and TcdB are not essential for the toxins biological
function, albeit determining the potency of the toxin by their
interactions with cell surface structures. Furthermore, we moni-
tored huge variations in toxin potency towards different cell types
as well as between the applied toxin forms. It should be noted that,
contrary to other analyzed cell lines, CHO-C6 cells show identical
susceptibility towards CROP-deleted and full length TcdA
whereas the CROP-truncated mutant of TcdB possesses less
potency towards these cells compared to the full length toxin. This
is important, because CHO cells are of hamster origin, and the
Syrian hamster model is widely used for C. difficile infection models
[27]. Thus, if CHO cells are representative for hamster cells
including enterocytes and colonocytes, studies on the relevance of
toxins only have model character [28] and their extrapolation to
human pathogenicity is limited. Different cells/species may
notedly differ in their sensitivity to TcdA and TcdB. In addition,
fragments or isoforms of toxins devoid of only the C-terminal
repeats are also pathogenic. The latter finding might be of
epidemiologic relevance with respect to the increasing prevalence
of TcdA
2/TcdB
+ C. difficile strains. These strains are designated as
TcdA-negative though, regarding serogroup F-strains, mere
lacking 1800 base pairs within the repetitive regions [29,30].
The resulting truncated TcdA lacking short parts of the CROP
domain is cytopathic and most likely accounts for the pathogenesis
observed in the variant C. difficile strains.
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